Nectar Lifesciences Limited has informed the Exchange about Intimation of inter-corporate loan agreement with Avensis Exports Private Limited, a Wholly Owned Subsidiary of the Nectar Lifesciences Limited
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences Limited has signed an inter-corporate loan agreement on March 11, 2026, to lend up to ₹100 crore to its wholly owned subsidiary, Avensis Exports Private Limited (AEPL). The loan is unsecured, carries a simple interest rate of 12% per annum, and has a fixed tenure of 10 years from the date of first disbursement. AEPL will use the funds for its general corporate purposes and business requirements. The transaction qualifies as a related party transaction (since AEPL is a 100% subsidiary) but is being carried out at arm's length, and the agreement does not grant any special rights such as director appointment or share subscription priority.
For shareholders, this is an internal capital allocation move rather than new external borrowing — the company is deploying up to ₹100 crore into its own subsidiary at a healthy 12% interest yield. The long 10-year tenor and unsecured nature mean repayment depends entirely on AEPL's business performance, so investors should watch the subsidiary's progress and any eventual recovery of these funds.